KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC
A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic